Dermal filler compositions for fine line treatment

Abstract

The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions which are particularly advantageous for correction of fine lines in the face.

What is claimed is: 
     
         1 . A dermal filler composition comprising hyaluronic acid and a vitamin C derivative covalently conjugated to the hyaluronic acid. 
     
     
         2 . The dermal filler composition of  claim 1 , wherein the vitamin C derivative is conjugated with the hyaluronic acid with a degree of conjugation of between about 3 mol % and about 15 mol %. 
     
     
         3 . The dermal filler composition of  claim 1 , wherein the vitamin C derivative is converted into vitamin C in vivo by enzymatic cleavage. 
     
     
         4 . The dermal filler composition of  claim 1 , wherein the vitamin C derivative is selected from ascorbic acid 2-glucoside (AA2G), ascorbyl 3 aminopropyl phosphate and sodium ascorbyl phosphate (AA2P). 
     
     
         5 . The dermal filler composition of  claim 4 , wherein the vitamin C derivative is ascorbic acid 2-glucoside (AA2G). 
     
     
         6 . The dermal filler composition of  claim 4 , wherein the vitamin C derivative is ascorbyl 3-am inopropyl phosphate. 
     
     
         7 . The dermal filler composition of  claim 4 , wherein the vitamin C derivative is sodium ascorbyl phosphate (AA2P). 
     
     
         8 . The dermal filler composition of  claim 1 , wherein the hyaluronic acid is crosslinked. 
     
     
         9 . The dermal filler composition of  claim 8 , wherein the hyaluronic acid is crosslinked with 1,4-butanediol diglycidyl ether (BDDE), pentaerythritol glycidal ether (Star-PEG epoxide), pentaerythritol (3-aminopropyl) ether (Star-PEG amine), or lysine. 
     
     
         10 . The dermal filler composition of  claim 9 , wherein the hyaluronic acid is crosslinked with 1,4-butanediol diglycidyl ether (BDDE). 
     
     
         11 . The dermal filler composition of  claim 9 , wherein the hyaluronic acid is crosslinked with lysine. 
     
     
         12 . The dermal filler composition of  claim 1 , further comprising an anesthetic agent. 
     
     
         13 . The dermal filler composition of  claim 12 , wherein the anesthetic agent is lidocaine. 
     
     
         14 . A method for treating a soft tissue condition in a subject in need thereof, the method comprising: administering a dermal filler composition comprising hyaluronic acid and a vitamin C derivative covalently conjugated to the hyaluronic acid. 
     
     
         15 . The method of  claim 14 , wherein the soft tissue condition is a wrinkle or scar. 
     
     
         16 . The method of  claim 14 , wherein the dermal filler composition releases the vitamin C derivative in the subject in need thereof for at least about 1 month and up to about 20 months. 
     
     
         17 . The method of  claim 14 , wherein the vitamin C derivative is covalently conjugated to the hyaluronic acid with BDDE or lysine. 
     
     
         18 . The method of  claim 14 , wherein the vitamin C derivative is selected from ascorbic acid 2-glucoside (AA2G), ascorbyl 3 aminopropyl phosphate and sodium ascorbyl phosphate (AA2P). 
     
     
         19 . The method of  claim 14 , wherein the vitamin C derivative is AA2G. 
     
     
         20 . The method of  claim 14 , wherein the vitamin C derivative is AA2P.